期刊文献+

拉米夫定联合α1胸腺肽治疗慢性乙型肝炎的疗效观察 被引量:11

下载PDF
导出
摘要 目的观察拉米夫定联合α1胸腺肽治疗慢性乙型肝炎的疗效和安全性。方法A组35例患者给予拉米夫定100mg口服,1次/d,治疗12个月,前6个月同时给予α1胸腺肽1.6mg,皮下注射,一周2次;B组仅给予拉米夫定100mg口服,1次/d,疗程12个月。两组均随访6个月,期间继续服拉米夫定。结果联合组与单用拉米夫定组在HBVDNA转阴方面疗效相近,但拉米夫定联合α1胸腺肽治疗可降低或减少YMDD变异。结论拉米夫定联合α1胸腺肽治疗无明显毒副作用,治疗安全性良好。
出处 《实用肝脏病杂志》 CAS 2007年第5期344-345,共2页 Journal of Practical Hepatology
  • 相关文献

参考文献10

二级参考文献30

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2Lau DT-Y, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Heoatology .2000,32:828-834.
  • 3Chen RN, Liaw YF, Chen TC, et al. Efficacy of thymosin in patients with chronic hepatitis B : A randomized, controlled trial. Hepatolotgy, 1998,27: 1383-1387.
  • 4Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.Hepatology, 1998,27:628-633.
  • 5Schiff ER, Heathcote J, Pastore G, et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy. Hepatology,2000,32 :296A.
  • 6Kirishima Toshihiko, Okanoue Takeshi, Daimon Yukiko, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients befor and during lamivudine treatment [J]. J Hepatol,2002,37:259-265.
  • 7骆抗先.乙型肝炎基础和临床[M].北京:人民卫生出版社,2001.337-338.
  • 8Liaw YF, Leung N, Guan R, et al. Asia-Pacific consensns statement on the management of chronic hepatiting B: an update[ J ]. J Gastroenterol Hepatol, 2003, 18 : 239 - 245.
  • 9Leung NWY, Lai CL, Chang TT, et al. Three year lamivudne theropy in chronic HB[J].J Hepatol, 1999, 30(Suppl, 1):59.
  • 10Santantonio T,Mazzola M,Pastore G.Lamivudine is safe and effective in fulminant hepatitis B[J].J Hepatol,1999,30 (3):551.

共引文献14124

同被引文献89

引证文献11

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部